[1] Sobel JD.Vulvovaginal candidosis[J].The Lancet,2007,369(9577):1961-1971.
[2] Kurtzman C,Robnett C.Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5'end of the large-subunit (26S) ribosomal DNA gene[J].J Clin Microbiol,1997,35(5):1216-1223.
[3] CLSI.Reference method for broth dilution antifungal susceptibility testing of yeasts;approved standard;CLSI document M27-A3[S].2008.
[4] CLSI.Reference method for broth dilution antifungal susceptibility testing of yeasts;Fourth informational supplement (M27-S4)[S].2012.
[5] Pfaller M,Messer S,Boyken L,et al.Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp[J].J Clin Microbiol,2004,42(7):3137-3141.
[6] Guinea J,Peláez T,Recio S,et al.In vitro antifungal activities of isavuconazole (BAL4815),voriconazole,and fluconazole against 1,007 isolates of Zygomycete,Candida,Aspergillus,Fusarium,and Scedosporium species[J].Antimicrob Agents Ch,2008,52(4):1396-1400.
[7] Marcos-Arias C,Eraso E,Madariaga L,et al.In vitro activities of new triazole antifungal agents,posaconazole and voriconazole,against oral Candida isolates from patients suffering from denture stomatitis[J].Mycopathologia,2012,173(1):35-46.
[8] Workowski KA,Bolan GA.Sexually transmitted diseases treatment guidelines (2015)[J].Reproductive Endocrinology,2015,(24):51-56.
[9] 魏文华,曲秀君,胡欣,等.抗真菌药物研究进展[J].中国现代药物应用,2012,6(23):111-112.
[10] Sobel JD,Chaim W,Nagappan V,et al.Treatment of vaginitis caused by Candida glabrata:use of topical boric acid and flucytosine[J].Am J Obstet Gynecol,2003,189(5):1297-1300.
[11] Phillips AJ.Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories[J].Am J Obstet Gynecol,2005,192(6):2009-2012.
[12] White D,Habib A,Vanthuyne A,et al.Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections[J].Sex Transm Infect,2001,77(3):212-213.
[13] Hetticarachchi N,Ashbee HR,Wilson JD.Prevalence and management of non-albicans vaginal candidiasis[J].Sex Transm Infect,2010,86(2):99-100.
[14] das Neves J,Pinto E,Teixeira B,et al.Local treatment of vulvovaginal candidosis[J].Drugs,2008,68(13):1787-1802.
[15] Tietz H-J.Treatment of chronic vulvovaginal candidiasis with posaconazole and ciclopiroxolamine[J].Health,2010,2(06):513.
[16] Seifert H,Aurbach U,Stefanik D,et al.In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates[J].Antimicrob Agents Ch,2007,51(5):1818-1821.
[17] Pfaller M,Messer S,Hollis R,et al.In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp[J].Antimicrob Agents Ch,2002,46(6):1723-1727.
[18] Ying C,Zhang H,Tang Z,et al.Antifungal susceptibility and molecular typing of 115 Candida albicans isolates obtained from vulvovaginal candidiasis patients in 3 Shanghai maternity hospitals[J].Sabouraudia,2015,54(4):394-399.
[19] 杨连娟,高志琴,顾伟鸣,等.67例阴道念珠菌病临床分析及药敏试验[J].中国真菌学杂志,2008,(06):346-348.
[20] 王东江,郭建,周爱萍,等.外阴阴道念珠菌病病原谱及抗真菌药物敏感性特征[J].检验医学,2016,(09):750-754.
[21] 吴永琴,王志恒,高晶,等.外阴阴道念珠菌病患者耐氟康唑白念珠菌克隆流行分析[J].中国感染与化疗杂志,2017,(03):321-325.